Skip to content

Search

Showing results for "lung disease preterm"

Funding the future of our research

Dr Anthony Bosco, Professor Steve Stick, Professor Andrew Whitehouse, Dr Raelene Endersby and Dr Luke Garratt know how fortunate they are to have

Families shape future of Down syndrome care

A collaborative study between UWA, Perth Children’s Hospital, The Kids and advocacy and support group Down Syndrome WA, has identified the top priorities, according to patients and carers, for clinical care and research for children with the genetic cond

Government grants to support valuable new child health research

Eight The Kids Research Institute Australia-led projects will benefit from the latest round of WA Child Research Fund (WACRF) grants, announced this week by Medical Research Minister Stephen Dawson.

Taking on a common respiratory infection in kids

Mapping when Respiratory Syncytal Virus (RSV) reaches its seasonal peak will assist how future vaccination programs are carried out.

Introducing our inaugural Illuminate Award recipients

We are excited to announce the winners of our inaugural Illuminate Awards

International trial shows that interferon could help reduce the spread of COVID-19

Results of an innovative clinical trial led by Perth researchers have shown that the drug interferon could help reduce the spread of COVID-19 from a positive person to their household contacts, with the study helping to inform treatment options for a future pandemic.

Wal-yan Scientific Retreat: Fostering Collaborative Excellence

The Wal-yan Respiratory Research Centre's dedicated team members, along with special guests, embarked on a journey to Wadjemup (Rottnest Island) on 9 and 10 November. 

The Platform Trial In COVID-19 priming and BOOsting : The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2

PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.

Beyond Seizures as an Outcome Measure: A Global Severity Scoring System for CDKL5 Deficiency Disorder

CDKL5 deficiency disorder (CDD) is a rare developmental and epileptic encephalopathy (DEE) associated with multiple impairments and comorbidities. Outcome measures for disease-modifying clinical trials for DEEs should measurably capture a spectrum of caregiver priorities and be externally validated.

Skin Microbiome

The skin is home to an array of bacteria, fungi and viruses, which together make up the skin microbiome. We explore how the skin microbiome can contribute to healthy skin.